Research programme: cyclin-dependent kinase 3 inhibitors - Senex Biotechnology
Latest Information Update: 01 Jul 2016
At a glance
- Originator Senex Biotechnology
- Class Small molecules
- Mechanism of Action Cyclin-dependent kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Colorectal cancer
Most Recent Events
- 01 Jul 2016 Preclinical trials in Colorectal cancer in USA (unspecified route)